Stockscreener 앱 받기
0.94
0.00%
0.00
시간 외 거래:
.91
-0.03
-3.19%
Io Biotech Inc 주식(IOBT)의 최신 뉴스
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - Morningstar
Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - Yahoo Finance
Melanoma FDA Approvals, Pipeline Insights, Clinical Trials Assessment and Companies | DelveInsight - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - MSN
Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor - Healio
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40) - Marketscreener.com
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - The Manila Times
IO Biotech Fast-Tracks Cancer Vaccine Trial, Completes Phase 2 Enrollment Early - StockTitan
5 Best Microbiome Companies (January 2025) - Securities.io
IO Biotech faces possible Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
IO Biotech faces possible Nasdaq delisting over low stock price - Investing.com India
IO Biotech Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement - Defense World
IO Biotech's chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Australia
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in December - MarketBeat
IO Biotech’s chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Nigeria
IO Biotech's chief medical officer acquires $26,553 in common stock - Investing.com
Io biotech general counsel Devin Smith acquires $9,720 in shares By Investing.com - Investing.com Nigeria
IO Biotech CEO Mai-Britt Zocca acquires $10,120 in company stock - Investing.com India
IO Biotech (NASDAQ:IOBT) Adopts Amended and Restated Bylaws - Defense World
Io biotech general counsel Devin Smith acquires $9,720 in shares - Investing.com India
IO Biotech CFO Amy Sullivan buys $8,482 in common stock By Investing.com - Investing.com Nigeria
IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock - MarketBeat
IO Biotech CFO Amy Sullivan buys $8,482 in common stock - Investing.com
IO Biotech Secures €57.5 Million Debt Financing from European Investment Bank - Defense World
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
IO Biotech amends bylaws and adjusts fiscal year-end By Investing.com - Investing.com UK
Cancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA - openPR
(PDF) 756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) - ResearchGate
Cancer Vaccines Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - Barchart
Cancer Vaccines Market Forecasted to Surge in Coming Years, - openPR
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight - Barchart
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: - openPR
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
IO Biotech stock hits 52-week low at $0.73 amid market challenges - Investing.com UK
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
5.49%
0.79%
자본화:
|
볼륨(24시간):